Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"
Completed
Westat
Phase 3
2019-05-30
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo
once every two weeks administered via "IV Push". An initial "Sentinel Group" of 5
participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing
concentration and decreasing administration time until undiluted IV Push over 30 seconds is
achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the
Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo
via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored.
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push"
Completed
TaiMed Biologics Inc.
Phase 3
2019-05-30
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo
once every two weeks administered via "IV Push". An initial "Sentinel Group" of 5
participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing
concentration and decreasing administration time until undiluted IV Push over 30 seconds is
achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the
Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo
via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
